Stock Quote

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, COVID-19, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

 

News Releases
Feb 26, 2021

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune...

Feb 18, 2021

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune...

Feb 17, 2021

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune...

View More

Upcoming Event
Thursday, February 25, 2021 - Saturday, February 27, 2021

View More

Contact Us

Immunic, Inc.
Jessica Breu
Head of IR and Communications
+49 89 2080 477 09
jessica.breu@imux.com

Rx Communications
Melody Carey
+1 917 322 2571
immunic@rxir.com

Fast Facts
  •  Company founded in 2016
  •  3 development programs
  •  Headquartered in the United States
  •  NASDAQ: IMUX
  •  Experts in selective oral drugs in immunology
Subscribe
To receive all investor alerts please subscribe here
* Required Fields